AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10870740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic opioid therapy
Number of subjects: 0
Study 9014776 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 20 mU/min
Number of subjects: 26
Study 9014776 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 30 mU/min
Number of subjects: 26
Study 9014776 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 50 mU/min
Number of subjects: 26
Study 9014776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1643195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg/70 kg
Number of subjects: 6
Study 1643195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg/70 kg
Number of subjects: 6
Study 1643195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 or 10 mg/70 kg)
Number of subjects: 6
Study 1643195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6487547 — intervention group
Group type: EXPERIMENTAL
Intervention: Minutes' therapy with dithranol in Lassar's paste
Number of subjects: 33
Study 6487547 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-contact therapy with dithranol in Lassar's paste
Number of subjects: 33
Study 6487547 — intervention group
Group type: COMPARATOR
Intervention: Standard Ingram regime of 24-hour application
Number of subjects: 33
Study 31389333 — intervention group
Group type: EXPERIMENTAL
Intervention: COPe-support (Carers fOr People with Psychosis e‐support) eHealth intervention
Number of subjects: 38
Study 31389333 — intervention group
Group type: EXPERIMENTAL
Intervention: COPe-support eHealth intervention
Number of subjects: 38
Study 29493524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 60
Study 29493524 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 60
Study 25245226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Number of subjects: 300
Study 25245226 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 300
Study 23286422 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg x kg(‐1))
Number of subjects: 14
Study 23286422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21730779 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid combination treatment for 10 days after abscess drainage
Number of subjects: 183
Study 21730779 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 10 days after abscess drainage
Number of subjects: 183
Study 19074638 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat exposure (10 s)
Number of subjects: 34
Study 19074638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat exposure (10 s)
Number of subjects: 34
Study 19074638 — intervention group
Group type: COMPARATOR
Intervention: No oral exposure (10 s)
Number of subjects: 34
Study 19074638 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat exposure (20 min)
Number of subjects: 34
Study 19074638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat exposure (20 min)
Number of subjects: 34
Study 17122238 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural analgesia (EDA group)
Number of subjects: 16
Study 17122238 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with desflurane (control group)
Number of subjects: 16
Study 17122238 — intervention group
Group type: COMPARATOR
Intervention: Both groups (EDA and control)
Number of subjects: 16
Study 15589853 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant LH in addition to increased dose of FSH (group B)
Number of subjects: 128
Study 15589853 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dosage of FSH (group A)
Number of subjects: 128
Study 15589853 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional FSH and LH using hMG (group C)
Number of subjects: 128
Study 15589853 — intervention group
Group type: COMPARATOR
Intervention: Control group (D) with no need to increase FSH dose
Number of subjects: 128
Study 11510063 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with bupivacaine and fentanyl
Number of subjects: 0
Study 11510063 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural mepivacaine
Number of subjects: 0
Study 9425484 — intervention group
Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy
Number of subjects: 64
Study 9425484 — intervention group
Group type: COMPARATOR
Intervention: Dissection tonsillectomy
Number of subjects: 64
Study 8502522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral penicillin V
Number of subjects: 47
Study 8502522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin G
Number of subjects: 47
Study 8502522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin estolate
Number of subjects: 47
Study 8502522 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 3098425 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 0
Study 3098425 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 150 micrograms
Number of subjects: 0
Study 3098425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28094559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotonovela condition (translated into Dutch)
Number of subjects: 202
Study 28094559 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional brochure condition (in Dutch)
Number of subjects: 202
Study 28094559 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 202
Study 28094559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotonovela condition
Number of subjects: 202
Study 28094559 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional brochure condition
Number of subjects: 202
Study 28934191 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individualised aerobic exercise programme (n=29)
Number of subjects: 53
Study 28934191 — intervention group
Group type: COMPARATOR
Intervention: 12-week waiting control group (n=24)
Number of subjects: 53
Study 25269680 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Number of subjects: 29
Study 25269680 — intervention group
Group type: COMPARATOR
Intervention: Control group (telephone call without guidance on exercise)
Number of subjects: 29
Study 23137292 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac (chemomechanical debridement with EndoVac system)
Number of subjects: 125
Study 23137292 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (chemomechanical debridement with conventional irrigation and PDT)
Number of subjects: 125
Study 23137292 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac+PDT (chemomechanical debridement with EndoVac and PDT)
Number of subjects: 125
Study 23137292 — intervention group
Group type: COMPARATOR
Intervention: Control (chemomechanical debridement with conventional irrigation)
Number of subjects: 125
Study 21621394 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic ratio diet
Number of subjects: 38
Study 21621394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5:1 ketogenic ratio diet
Number of subjects: 38
Study 18646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized cross-over design
Number of subjects: 0
Study 18646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size formula for continuous outcomes
Number of subjects: 0
Study 16958775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner management (NURS) including individualized lifestyle modification and pharmacologic intervention for 1 year after discharge
Number of subjects: 228
Study 16958775 — intervention group
Group type: COMPARATOR
Intervention: Usual care (EUC) enhanced with feedback on lipids to their primary provider and/or cardiologist
Number of subjects: 228
Study 14665353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily) for 30 days before biopsy
Number of subjects: 66
Study 14665353 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tamsulosin treatment)
Number of subjects: 66
Study 14665353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin group
Number of subjects: 66
Study 14665353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 12823087 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b therapy (5 million units 3 times per week or 3 to 5 million units 3 times per week with ribavirin 1000-1200 mg/day)
Number of subjects: 104
Study 12823087 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b therapy
Number of subjects: 104
Study 12823087 — intervention group
Group type: COMPARATOR
Intervention: Untreated reference group
Number of subjects: 104
Study 10827325 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based trauma simulator
Number of subjects: 100
Study 10827325 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminar-based teaching
Number of subjects: 100
Study 10827325 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no additional teaching)
Number of subjects: 100
Study 10827325 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based trauma simulator and Seminar-based teaching
Number of subjects: 100
Study 8892128 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge planning and 8-week home follow-up provided by advanced practice nurses, including home visits, telephone outreach, and daily telephone availability.
Number of subjects: 61
Study 8892128 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (more than two required for more than half of the women), mean home visit time was 1 hour.
Number of subjects: 61
Study 2059530 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-headed toothbrush (Duodent 2000)
Number of subjects: 50
Study 2059530 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush (Oral B 32)
Number of subjects: 50
Study 6334974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibratory stimulation at 100 Hz applied directly to the pruritic area
Number of subjects: 12
Study 6334974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibratory stimulation at 10 Hz and 200 Hz
Number of subjects: 12
Study 6334974 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at 2 Hz and 100 Hz
Number of subjects: 12
Study 6334974 — intervention group
Group type: COMPARATOR
Intervention: Placebo conditioning procedure
Number of subjects: 12
Study 29768364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragility fracture integrated rehabilitation management (FIRM)
Number of subjects: 282
Study 29768364 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 282
Study 29768364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 282
Study 26979312 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 3.6 mg/kg every three weeks or 2.4 mg/kg weekly + paclitaxel 80 mg/m2 weekly ± pertuzumab 840 mg loading dose followed by 420 mg q3w
Number of subjects: 44
Study 26979312 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + paclitaxel ± pertuzumab
Number of subjects: 44
Study 24660647 — intervention group
Group type: EXPERIMENTAL
Intervention: Red laser therapy (4 J/cm2 in temporomandibular joints and 8 J/cm2 in muscles, three sessions)
Number of subjects: 19
Study 24660647 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser therapy (4 J/cm2 in temporomandibular joints and 8 J/cm2 in muscles, three sessions)
Number of subjects: 19
Study 21593809 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg sodium selenite/day for 3 weeks)
Number of subjects: 10
Study 21593809 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 10
Study 20504899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed insulins (insulin detemir mixed with aspart)
Number of subjects: 14
Study 20504899 — intervention group
Group type: COMPARATOR
Intervention: Separate insulins (insulin detemir and aspart given separately)
Number of subjects: 14
Study 17631952 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab + Ragweed immunotherapy
Number of subjects: 0
Study 17631952 — intervention group
Group type: COMPARATOR
Intervention: Ragweed immunotherapy alone
Number of subjects: 0
Study 15625202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts
Number of subjects: 30
Study 15625202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15625202 — intervention group
Group type: COMPARATOR
Intervention: Divalproex sodium
Number of subjects: 30
Study 12394374 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with long chain polyunsaturated fatty acids (F+LCP)
Number of subjects: 40
Study 12394374 — intervention group
Group type: COMPARATOR
Intervention: Formula without long chain polyunsaturated fatty acids (F)
Number of subjects: 40
Study 9706918 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 5 microg/kg p.o. (Group C)
Number of subjects: 35
Study 9706918 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 60 microg/kg p.o. (Group L)
Number of subjects: 35
Study 9706918 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg plus scopolamine 6 microg/kg i.m. (Group M)
Number of subjects: 35
Study 8907407 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI prevention program (videotape, slides, textbook, manual)
Number of subjects: 208
Study 8907407 — intervention group
Group type: COMPARATOR
Intervention: Traditional curriculum (control group)
Number of subjects: 208
Study 2403593 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of a drug by the capillary cloning system
Number of subjects: 133
Study 2403593 — intervention group
Group type: COMPARATOR
Intervention: Selection of a drug by the clinician
Number of subjects: 133
Study 2403593 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate for all patients
Number of subjects: 133
Study 2403593 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 133
Study 76798 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor from random normal donors
Number of subjects: 16
Study 76798 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study 30476931 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0
Study 30476931 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized
Number of subjects: 0
Study 29071967 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified acupuncture at Renying point (ST 9)
Number of subjects: 59
Study 29071967 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture technique
Number of subjects: 59
Study 26164120 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (participants listed what fruits and vegetables they would eat and when and where they would eat them)
Number of subjects: 108
Study 26164120 — intervention group
Group type: COMPARATOR
Intervention: Control condition (participants did not list fruits and vegetables)
Number of subjects: 108
Study 26164120 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (replicated in Experiment 2)
Number of subjects: 108
Study 23200303 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (80 mg/day; p.o.)
Number of subjects: 50
Study 23200303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21656068 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 80
Study 21656068 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 80
Study 18754988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone intervention for smoking cessation
Number of subjects: 50
Study 18754988 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonabused women)
Number of subjects: 50
Study 16423200 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic pregnant women
Number of subjects: 50
Study 12603366 — intervention group
Group type: EXPERIMENTAL
Intervention: Behçet's Disease patients
Number of subjects: 27
Study 12603366 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 27
Study 11337976 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA supplementation (3.9 g/d)
Number of subjects: 17
Study 11337976 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (control group)
Number of subjects: 17
Study 9152654 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I (presence of vital exhaustion)
Number of subjects: 2449
Study 9152654 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II (no vital exhaustion, depression, low levels of anxiety)
Number of subjects: 2449
Study 9152654 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behaviour among patients eligible for exercise test
Number of subjects: 2449
Study 9152654 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of neuroticism and extroversion
Number of subjects: 2449
Study 9152654 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables (exercise test ineligibility, late and early ventricular failure)
Number of subjects: 2449
Study 7515651 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVmP-VB
Number of subjects: 346
Study 7515651 — intervention group
Group type: COMPARATOR
Intervention: ProMACE-MOPP
Number of subjects: 346
Study 2439456 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% modified fluid gelatine
Number of subjects: 87
Study 2439456 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% low molecular hydroxyethyl starch
Number of subjects: 87
Study 2439456 — intervention group
Group type: COMPARATOR
Intervention: Both plasma substitutes
Number of subjects: 87
Study 2205704 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (15 mg)
Number of subjects: 349
Study 2205704 — intervention group
Group type: COMPARATOR
Intervention: atenolol (100 mg)
Number of subjects: 349
Study 788694 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (1 mg, orally, every 6 hours for two weeks)
Number of subjects: 10
Study 788694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prostaglandin treatment)
Number of subjects: 10
Study 30972693 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 14.29% (Group A)
Number of subjects: 33
Study 30972693 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 12.47% (Group B)
Number of subjects: 33
Study 30972693 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 10.82% (Group C)
Number of subjects: 33
Study 30972693 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 28693558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of elemental zinc orally for 14 days
Number of subjects: 0
Study 28693558 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally for 14 days
Number of subjects: 0
Study 25182142 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 g almonds
Number of subjects: 32
Study 25182142 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 g almonds
Number of subjects: 32
Study 25182142 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g almonds)
Number of subjects: 32
Study 25182142 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective appetite ratings
Number of subjects: 32
Study 24022423 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (8 oz)
Number of subjects: 30
Study 24022423 — intervention group
Group type: COMPARATOR
Intervention: Warm water (8 oz)
Number of subjects: 30
Study 21435092 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy (esomeprazole and amoxicillin for 7 days followed by esomeprazole, amoxicillin, clarithromycin, and metronidazole for 7 days)
Number of subjects: 117
Study 19394618 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg daily
Number of subjects: 2860
Study 19394618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2860
Study 16698320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses trained in the stages of change model for counselling
Number of subjects: 19
Study 12939536 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and jumping training (WJG)
Number of subjects: 28
Study 12939536 — intervention group
Group type: COMPARATOR
Intervention: Walking training (WG)
Number of subjects: 28
Study 10824446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 1%
Number of subjects: 170
Study 10824446 — intervention group
Group type: COMPARATOR
Intervention: Terconazole 0.8%
Number of subjects: 170
Study 8890507 — intervention group
Group type: EXPERIMENTAL
Intervention: Still-face-with-touch (intervention)
Number of subjects: 48
Study 8890507 — intervention group
Group type: COMPARATOR
Intervention: Still-face-no-touch (control)
Number of subjects: 48
Study 1832313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 673
Study 1832313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study 6606421 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1.92g dose of co-trimoxazole
Number of subjects: 44
Study 6606421 — intervention group
Group type: COMPARATOR
Intervention: 5-day course of co-trimoxazole
Number of subjects: 44
Study 31063478 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 kcal/session exercise group
Number of subjects: 104
Study 31063478 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 kcal/session exercise group
Number of subjects: 104
Study 31063478 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 27892881 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of coronary stenosis
Number of subjects: 929
Study 27892881 — intervention group
Group type: COMPARATOR
Intervention: Quantitative coronary angiography (QCA)
Number of subjects: 929
Study 26356160 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamid
Number of subjects: 207
Study 26356160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 26356160 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamid (after placebo phase)
Number of subjects: 207